Using Enzo's newest technology platform, LRP cell signaling modulation, we have identified several compounds with potential for treating bone disorders.
One of several candidate drugs, when injected subcutaneously, was shown to induce new bone formation in mouse calvaria, the flat bones that comprise the top of the skull. When delivered orally the compound prevented alveolar bone loss in an endotoxin-induced periodontitis rat model.
These proprietary candidate compounds were identified through an innovative approach that combines structural biology, computational screening, mutational analyses and biological in vitro assays, followed by in vivo animal model systems.
We continue to synthesize and develop these and other novel compounds that show activity in animal models that assess bone density and we are moving them through the drug development continuum.